CCL18/PARC is a chemotactic cytokine involved in the pathogenesis and progression of various disorders, including cancer. Proof showed high levels of CCL18/PARC in the serum of epithelial ovarian carcinoma patients sμggesting its potential as a circulating biomarker. CCL18/PARC chemokine has an important role in chemokine-mediated tumor metastasis, and may serve as a potential predictor for poor survival outcomes for ovarian cancer. (CCL18/PARC) is predominantly secreted by M2-tumor associated macrophages (TAMs) and promotes malignant behaviors of various human cancer types. CCL18/PARC has a correlation with cardiac function in patients with AAMI and it might be considered as an indicator of poor LVEF in patients with AAMI. Circulating and WAT-secreted CCL18/PARC correlates with insulin resistance and metabolic risk score. Because CCL18/PARC is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of WAT inflammation. Macrophages are thoμght to be the main source of CCL18/PARC, and the effect of pirfenidone, an anti-fibrotic agent for idiopathic pulmonary fibrosis, on the expression of CCL18/PARC in macrophages warrants investigation.

Codice: PDEH100610_100μg | Marca: Elabscience | Confezionamento: 100μg